...
首页> 外文期刊>Thyroid: official journal of the American Thyroid Association >Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
【24h】

Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.

机译:评价111铟五肽生长激素抑制素受体闪烁显像技术以检测放射性碘闪烁显像阴性的复发性甲状腺癌。

获取原文
获取原文并翻译 | 示例

摘要

The follow-up of patients who underwent thyroidectomy for differentiated thyroid carcinoma is based on the combination of serum thyroglobulin (Tg) measurement and radioiodine total-body scan (ITBS). The diagnostic strategy to be used in patients with elevated serum Tg level but negative ITBS remains debatable. Somatostatin receptor scintigraphy (SRS) has been proposed. Our objective was to compare the results of SRS and conventional radiological imaging (CRI) for the diagnosis of recurrent disease and/or metastases in 15 patients who had had thyroidectomy for differentiated carcinoma (14 papillary, 1 Hurthle cell carcinoma) and who displayed elevated Tg levels (10 to 65000 ng/mL) together with negative ITBS performed after 100 mCi. All patients underwent SRS and CRI within 3 months, allowing comparison of the 2 approaches for the identification of thyroid carcinoma metastases. CRI first included a chest x-ray and ultrasonography of the neck. It was followed by computed tomography (CT) scanning and/or magnetic resonance imaging (MRI) of the neck, chest and occasionally abdomen, and 99mTc bone scintigraphy in case of negative results. In 6 patients with Tg levels ranging from 65 to 65000 ng/mL, CRI detected 12 histologically proven metastases among 9 organs. Among these patients, SRS identified only 6 metastases. SRS identified 1 case of mediastinal recurrence that was not detected by CRI. In another patient with a Tg level of 51 ng/mL, a cervical node was identified using both SRS and CRI but proved to be a false-positive (inflammatory cervical node). In the other 8 patients with Tg levels ranging from 10 to 580 ng/mL, SRS and CRI were negative, and the source of Tg secretion remains unknown. The results of SRS did not correlate with serum Tg level. In conclusion, the diagnostic accuracy of SRS in this study was disappointing and clearly lower than that of CRI. Our results do not support the use of SRS as a guide conventional imaging modalities in patients operated on for differentiated thyroid carcinoma who display elevated Tg levels together with negative ITBS.
机译:对甲状腺癌患者行分化型甲状腺癌的随访是基于血清甲状腺球蛋白(Tg)测量和放射性碘全身扫描(ITBS)的组合。血清Tg水平升高但ITBS阴性的患者的诊断策略仍有待商.。已经提出了生长抑素受体闪烁显像术(SRS)。我们的目的是比较SRS和常规放射学成像(CRI)的结果,以诊断15例行甲状腺癌的分化型癌(14例乳头状瘤,1个Hurthle细胞癌)并显示Tg升高的患者的复发性疾病和/或转移灶100 mCi后执行ITBS阴性(10至65000 ng / mL)和阴性ITBS。所有患者均在3个月内接受了SRS和CRI,从而可以比较两种鉴定甲状腺癌转移的方法。 CRI首先包括胸部X光检查和颈部超声检查。随后进行颈部,胸部和偶尔腹部的计算机断层扫描(CT)扫描和/或磁共振成像(MRI),如果结果阴性,则进行99mTc骨闪烁显像。在6例Tg水平为65至65000 ng / mL的患者中,CRI在9个器官中检测到12个组织学证实的转移灶。在这些患者中,SRS仅发现了6个转移灶。 SRS确定了1例CRI未发现的纵隔复发病例。在另一位患者的Tg水平为51 ng / mL的患者中,同时使用SRS和CRI识别出了颈部淋巴结,但被证明是假阳性(炎性宫颈淋巴结)。在其他8例Tg水平为10至580 ng / mL的患者中,SRS和CRI均为阴性,并且Tg分泌的来源仍然未知。 SRS的结果与血清Tg水平无关。总之,本研究中SRS的诊断准确性令人失望,明显低于CRI。我们的结果不支持将SRS用作在分化型甲状腺癌手术患者中显示Tg升高和ITBS阴性的常规影像学方法的指南。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号